Corrigendum to "Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study" EClinicalMedicine. 2025 Jul 25:86:103383.
Where this comes from
- Record sourced from PubMed, PMID 42011218.
- Also identified by DOI 10.1016/j.eclinm.2026.103904 and PMC identifier 13091732.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
[This corrects the article DOI: 10.1016/j.eclinm.2025.103383.].